Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

92
Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
92
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

176
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
176
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

127
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
127
Hazard Ratio01:12

Hazard Ratio

110
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
110
Actuarial Approach01:20

Actuarial Approach

74
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
74

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does prior percutaneous coronary revascularization negatively affect the outcomes of subsequent coronary artery bypass grafting?

The Annals of thoracic surgery·2026
Same author

Transcatheter vs surgical aortic valve implantation: age vs lifetime perspective.

European heart journal·2026
Same author

Great debate: surgical aortic valve replacement is first choice for aortic stenosis in patients with a life expectancy beyond 5 years.

European heart journal·2026
Same author

Improving the diagnostic performance of troponin assays for acute myocardial infarction in renal impairment.

Heart (British Cardiac Society)·2026
Same author

Systematic Review and Reconstructed Individual Patient Data of Atherosclerotic Subclavian Artery Aneurysm in the Endovascular Era.

Annals of vascular surgery·2026
Same author

A 20-year UK multi-center experience of combined surgical aortic valve replacement and coronary artery bypass grafting.

Expert review of cardiovascular therapy·2026
Same journal

Continuing authorship proliferation in the cardiothoracic surgical literature.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same journal

Marked response to immunochemotherapy in airway mucosal recurrence of lung squamous cell carcinoma.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same journal

Computed tomography-derived fractional flow reserve versus transit-time flow measurement for predicting early competitive graft flow after coronary artery bypass grafting.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same journal

Video-assisted transcervical-transtracheal repair for post-intubation tracheal laceration.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same journal

Urgent Resection of Hepatocellular Carcinoma with Intracardiac Extension under Moderate Hypothermic Circulatory Arrest.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same journal

Comparison of Cannulation Strategies for Minimally Invasive Mitral Valve Surgery.

Interdisciplinary cardiovascular and thoracic surgery·2026
See all related articles

Related Experiment Video

Updated: Jun 22, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K

Composite end points and competing risks analysis.

Victor Dayan1, Stuart W Grant2, James M Brophy3

  • 1Centro Cardiovascular Universitario, Cardiac Surgery Department, Hospital de Clinicas, Universidad de la Republica, Montevideo, Uruguay.

Interdisciplinary Cardiovascular and Thoracic Surgery
|July 2, 2024
PubMed
Summary
This summary is machine-generated.

Composite end points in clinical trials increase event numbers, reducing participant needs. This primer discusses key considerations for designing and interpreting these complex outcomes.

Keywords:
Competing risksComposite outcomesStatistics

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

248

Related Experiment Videos

Last Updated: Jun 22, 2025

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.0K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

248

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Medical Research Methodology

Background:

  • Composite end points are frequently used as primary outcomes in clinical trials.
  • Their primary advantage is increasing the number of observed events, thus requiring fewer participants for adequate statistical power.
  • They allow for the inclusion of multiple important clinical endpoints, potentially enhancing the detection of clinically meaningful treatment effects and avoiding outcome hierarchy issues.

Purpose of the Study:

  • To provide a statistical primer on composite end points in clinical trials.
  • To discuss critical considerations in the design and interpretation of trials using composite outcomes.
  • To highlight potential challenges and advanced methods related to composite end points.

Main Methods:

  • Discussion of statistical concepts relevant to composite end points.
  • Examination of issues including competing events, halo effect, and risk of bias.
  • Exploration of time-to-event limitations and the win ratio methodology.

Main Results:

  • Composite end points offer statistical power benefits but require careful handling.
  • Potential biases and limitations such as competing events and time-to-event issues can impact interpretation.
  • Advanced statistical approaches like the win ratio may offer solutions for complex scenarios.

Conclusions:

  • Careful consideration of design and interpretation is crucial for composite end points.
  • Understanding limitations like competing events and bias is essential for valid clinical trial conclusions.
  • The use of composite end points necessitates a nuanced statistical approach to ensure accurate and reliable results.